Plasma extracellular vesicles of neuronal and astrocytic origins: Biomarker carriers and pathogenic effectors in Alzheimer’s disease

Dimitrios Kapogiannis,Erden Eren,Jack F.V. Hunt,Michelle Shardell,Nicholas M. Vogt,Sterling C. Johnson,Barbara B. Bendlin,Carlos Nogueras‐Ortiz,Francheska Delgado‐Peraza,Erez Eitan

DOI: https://doi.org/10.1002/alz.037317

2020-12-01

Abstract:Abstract Background Circulating neuronal and astrocytic Extracellular Vesicles (NEVs, AEVs) provide biomarkers for Alzheimer’s disease (AD) (including total and p‐Tau in NEVs, complement in AEVs). In a large case‐control study leveraging Baltimore Longitudinal Study of Aging samples, Tau‐related NEV biomarkers predicted future AD diagnosis with high accuracy, sensitivity and specificity. To validate NEV Tau biomarkers for predicting cognitive decline in late middle‐age we leveraged Wisconsin Registry for Alzheimer’s prevention (WRAP) study samples. To examine convergent validity we used transgenic AD mice. Finally, we examined functional effects of circulating EVs. Methods We isolated NEVs and AEVs from plasma through immunocapture against L1CAM and GLAST respectively. Total and p‐Tau were measured in 292 serum samples from 146 cognitively unimpaired WRAP participants, divided into longitudinal cognitive decliner and non‐decliner groups. We also measured Tau biomarkers in circulating NEVs and brains of 28 mice (4 2xTg, 15 3xTg, 9 WT). To study functional effects of circulating EVs, we co‐cultured AEVs and NEVs (from 8 AD patients, 8 controls) with rat cortical and human iPSC‐derived neurons and performed cell viability and neurodegeneration assays. Results In WRAP, cognitive status was associated with NEV Tau biomarkers depending on age, with cognitively declining compared to stable individuals showing higher pTau231 (p < 0.01), total Tau (p <0.001) and pTau181 (p < 0.05) with older age. Combining longitudinal NEV biomarkers achieved up to 94% area‐under‐curve (AUC), 86.0% sensitivity and 86.7% specificity for predicting cognitive decline. In mice, total Tau and pTau181 levels in circulating NEVs showed strong correlations with levels in cortex and hippocampus (p < 0.001; Figure: Fraction1 acquired ante‐mortem, Fraction 2 acquired during euthanasia). Functionally, AEVs (and, less effectively, NEVs) of AD patients induced complement Membrane Attack Complex deposition, membrane disruption, neurodegeneration, and necroptosis on recipient neurons. Neurodegenerative effects were not produced by total circulating EVs from AD patients or AEVs/NEVs from controls and were suppressed by complement inhibitors. Conclusions NEV Tau biomarkers predict cognitive decline in late middle‐age humans. Tau in circulating NEVs reflect brain levels in mice. Functionally, AD patients’ circulating AEV/NEVs are neurotoxic. Inhibition of EV‐associated complement components may be therapeutically beneficial in AD.